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Abstract
Community-acquired pneumonia (CAP) has significant morbidity and mortality. The Infectious
Diseases Society of America/American Thoracic Society (IDSA/ATS) guidelines recommend two
antimicrobial regimens for hospitalized patients with CAP, one of which includes a macrolide, and
one of which does not. Both regimens have antimicrobial properties, but macrolides also possess
immunomodulatory properties. Macrolides, however, may also have potential arrhythmia adverse
effects. The purpose of this review is to provide an update of studies evaluating outcomes for
patients with CAP treated with or without a macrolide-based regimen. Two recent randomized
controlled trials conflict with each other regarding the benefit versus noninferiority of including a
macrolide for the treatment for CAP. Each have their respective limitations. Most prior observa-
tional studies and meta-analyses favor using a regimen with a macrolide. We do not recommend
any different treatment strategy than the current IDSA/ATS guidelines for CAP. Further studies
need to occur to define the optimal treatment for CAP.
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1 Background
Community-acquired pneumonia (CAP) is the 8th leading cause
of death in the US.1 In this country, CAP is the most common
cause of admission to the ICU and causes the highest mortality of
any infectious disease. Inpatient mortality in a recent study of all
hospitalized patients in Louisville, KY (population ~600,000) was
6%.2 The Non-ICU mortality rate may be as low as 2%, while the
ICU mortality rate may be as high as 18%, or higher.3,4 Length
of stay accounts for the bulk of expenditure on CAP. It requires
a major contribution of resources for health care in the US. Es-
timates are ~$1000 per day for care on wards, $3800 to $5000
per day in the ICU.4 A total of $16 billion was spent for CAP in
2013.5
Streptococcus pneumoniae has been the primary pathogen isolated
for over a century in patients with CAP. The onset of resistance
to S. pneumoniae presented with the introduction of penicillin,
and has broadened to other β -lactams, macrolides, and fluoro-
quinolones as they have been introduced. A surveillance study of
71 centers in the US yielded 3329 consecutive samples.6 Resis-
tance to ceftriaxone was 2%, to erythromycin was 39%, and to
levofloxacin was 0.7%. Resistance of Haemophilus influenzae and
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Moraxella catarrhalis to the same three drugs was between zero
and 1.3%. Atypical pathogens (Legionella pneumophila, Chlamy-
dia pneumoniae, and Mycoplasma pneumoniae) have a worldwide
incidence up to 22%.7 β -lactams do not cover L. pneumophila
or C. pneumoniae because they are intracellular organisms, nor
do they cover M. pneumoniae because it lacks a cell wall, but
the pathogens are covered by macrolides and fluoroquinolones.
Staphylococcus aureus causes CAP more so now than in decades
past. Risk factors for CAP due to S. aureus include colonization
with S. aureus in the nares, performance in contact sports, injec-
tion drug use, men who have sex with men, and living in crowded
living conditions (including prison). Pseudomonas is rare in CAP,
but may occur in those with bronchiectasis or chronic obstruc-
tive pulmonary disease, especially after long-term antimicrobial
or glucocorticoid use. Treatment should be focused on the most
common pathogens in consideration with unique risk factors of
each patient.
The primary recommendation for the treatment for CAP by the
American Thoracic Society/Infectious Diseases Society of Amer-
ica is to provide ward patients with either a β -lactam plus a
macrolide or a fluoroquinolone.8 There has not been enough con-
vincing evidence for either regimen to favor one over the other.
In the ICU, a β -lactam is recommended to be combined with ei-
ther a macrolide or a fluoroquinolone. Other coverage is based
on risk factors for specific pathogens, such as methicillin-resistant
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S. aureus or Pseudomonas. Physicians should still exercise clinical
judgment as it is considered to be integral to the management of
CAP.9 Guideline-concordant therapy was shown to be associated
with improved outcomes in ICU patients and the elderly, but not
in ward patients.10–12
2 Macrolide antimicrobials
2.1 History of pathogen coverage
Macrolides were first discovered from the soil bacterium Strep-
tomyces erythraeus in the 1950s. Erythromycin contains a large
15 member ring. Azithromycin followed and is distinct from ery-
thromycin by having a single nitrogen substituted for a methyl
group. With this small change, azithromycin has better oral ab-
sorption with less gastrointestinal side effects, and a longer half
life. Although it is slightly less active than erythromycin for Strep-
tococcus pneumoniae, it has better coverage for H. influenzae, M.
cararrhalis and L. pneumophila.
2.2 Resistance
Resistance to macrolides is conferred by either efflux of the drug
from the cell or a target site alteration. The most notable efflux
mechanism, called the M phenotype, is expressed by S. pneumo-
niae. The gene mef(A) codes for an efflux pump that stretches
across the entire cytoplasmic membrane of S. pneumoniae and
pumps the macrolide out of the pathogen. The M phenotype is
the most predominant one in the US for S. pneumoniae.13 The
most predominant resistance phenotype in Europe is a target site
alteration referred to as MLSB phenotype.14 When methylation
of a specific adenine in the gene that codes for the 23S riboso-
mal RNA of the 50S ribosomal subunit occurs, it then confers
resistance to macrolides by several pathogens, including S. pneu-
moniae. This pattern of resistance, noted as MLSB phenotype,
is coded by the erm (erythromycin ribosome methylation) gene.
The enzyme that carries out methylation can be induced by low
levels of erythromycin. The "D" test was made popular when it
was used to verify the presence or absence of clindamycin resis-
tance to S. aureus. Samples that may have been initially found
to be "sensitive", were concluded to be "resistant" after inducible
resistance was detected in the presence of erythromycin.
2.3 Anti-inflammatory activity
Macrolides, in addition to having antimicrobial effects, have the
unique characteristic of anti-inflammatory effects. These include
inhibition of proinflammatory cytokines and proteins, such as nu-
clear factor κB, activating protein-1, interleukin (IL)-1, IL-6, IL-8
and tumor necrosis factor-α.15,16 Macrolides stimulate endothe-
lial cells to release nitric oxide while they alter epithelial cells
to resist pneumococci.17,18 Biofilm formation by bacteria is in-
terrupted while mucociliary clearance is increased.19 There is in-
terference with the production of reactive oxygen species (ROS)
by neutrophils.19 Finally, neutrophil apoptosis is accelerated, fa-
voring it over necrosis resulting in more programmed cell death
rather than caustic cell contents being released during necrosis.20
2.4 Adverse effects
Macrolides are more known for their side effects, such as nau-
sea, than adverse effects. When azithromycin was created sub-
stituting a nitrogen for a methyl group, absorption improved,
thus curbing the gastrointestinal effects. The alteration of the
molecule, however, did not alter the potential for arrhythmia.
The most well known adverse effect is QTc prolongation with po-
tential Torsades de Pointes leading to ventricular fibrillation and
death. A study of a Tennessee Medicaid database sought to deter-
mine if azithromycin, amoxicillin or a fluoroquinolone was asso-
ciated with cardiac-related death as compared to a control group
(no antimicrobial).21 Azithromycin was found to be associated
with cardiovascular death more so than amoxicillin (Hazard ratio
(HR); 95% confidence interval (CI) 1.38-4.50; P=0.002), or no
antimicrobial (HR 2.88; 95% CI 1.79-4.63; P<0.001). There was
no significant difference between azithromycin and levofloxacin
(P=0.18), but there was between azithromycin and ciprofloxacin
(HR 3.49; 95% CI, 1.32-9.26; P=0.01). For this reason, poten-
tial cardiac-related death should be considered when prescribing
anyone azithromycin or levofloxacin. It should be noted, how-
ever, that there were over 3.5 million patients included in this
study, which makes a difference between groups more likely to be
statistically significant. The proportions of patients affected were
very small (0.003% for amoxicillin and 0.008% for azithromycin).
At this time, neither azithromycin nor levofloxacin have a black
box warning related to arrhythmia.
Other large cohort studies found no effect or a protective ef-
fect of azithromycin on cardiovascular outcomes. The first study
was a similar age population among VA patients as the previous
study with Medicare patients.30 All patients had been hospital-
ized for pneumonia, and the mean age was 77 years. There
were almost 40,000 in each group studied: those who received
azithromycin and those who did not. The 30 d-day and 90-
day mortality were both statistically significantly lower in the
azithromycin group. The 90-day mortality in each group was
17.4% vs 22.3%; odds ratio 0.73 (95% CI 0.70-0.76). Among
four separate outcomes–any cardiovascular event, heart failure
and cardiac arrhythmia–were similar, while myocardial infarc-
tion occurred more in the azithromycin group; OR 1.11 (95% CI,
1.03-1.20). The other study included patients between ages 10-
64 years who did not necessarily have CAP, and were prescribed
either azithromycin (1.1 million episodes), penicillin V (7.4 mil-
lion episodes) or no antibiotic (1.1 million episodes).31 Mortal-
ity from cardiovascular causes for azithromycin was 1.1/1000
patient-years, which was compared to no antibiotic, 0.4/1000
patient-years (rate ratio 2.85; 95% CI, 1.13-7.24), and penicillin
V, 1.5/1000 patient-years (rate ratio 0.93; 95% CI, 0.56-1.55).
3 Literature Review
Attention has been given to compare a β -lactam plus a macrolide
versus a fluoroquinolone alone, which are the two regimens
recommended in the guidelines.8 In general, studies that have
shown a benefit of a macrolide containing regimen have been ob-
servational studies with a "real-world" population of mixed sever-
ities as measured by the pneumonia severity index or a version of
the CURB-65 (Confusion, blood Urea nitrogen level, Respiratory
rate, Blood pressure–age ≥65 years). Prospective, randomized
clinical trials (RCT) have opposite conclusions. Table 1 summa-
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Table 1 Efficacy of antimicrobial regimens with and without a macrolide for hospitalized patients with community-acquired pneumonia.
Study Year Method Population Regimens Outcomes Results comparing macrolide and
non-macrolide therapy
Gleason et al 22 1999 Observational 12,945 Medicare
patients ≥65 yrs
Ceph alone,
Ceph + Mac,
Quin alone
30-d mortality Cephalosporin alone worse than
other two regimens
Loh et al 23 2005 Prospective,
observational
141 non-severe and
severe patients
Mac vs
Non-mac
In-hospital
mortality
No difference between groups
Aspa et al 24 2006 Observational 638 patients with
pneumcoccal CAP
β -lac alone
β -lac + Mac
Quin alone
30-d mortality No difference between groups
Dwyer et al 25 2006 Prospective,
observational
370 patients with
pneumococcal
bacteremia
β -lac vs
β -lac + Mac
Mortality (not
specified)
No difference between groups
Lodise et al 26 2007 Observational 515 VA patients β -lac + Mac
vs Quin alone
14-d and 30-d
mortality
Combination group had better 14-d
mortality (full population), and 30-
d mortality (severe CAP only)
Metersky et al 27 2007 Observational 2,209 Medicare
patients
Non-mac vs
Mac
In-hospital mortality,
30-d mortality,
30-d readmit rate
All outcomes favored Mac group
Paul et al 28 2007 Prospective,
observational
451 patients; only 54
after propensity
analysis
β -lac vs
β -lac + Mac
30-d mortality β -lac + Mac group with favorable
difference, but not after statistical
adjustment
Restrepo et al 29 2009 Observational 237 patients with
severe sepsis
Mac vs Non-
mac
30-d and 90-d
mortality
Both outcomes favored Mac group
rizes pertinent studies.
The first of two RCTs was an open-label, multicenter Swiss
study in 2014 of 580 hospitalized patients, which divided pa-
tients between two arms: β -lactam alone versus β -lactam plus a
macrolide.32 The patients were immunocompetent and excluded
anyone presenting with a pneumonia severity index risk class of V,
therefore the primary outcomes were the proportion who reached
clinical stability within a week (59% for the monotherapy arm vs
66% for the combination therapy arm; P=0.07), and the 30-day
readmission rate (7.9% for the monotherapy arm vs 3.1% for the
combination therapy arm; P=0.01). Other outcomes did not dif-
fer including mortality, length of stay, transfer to ICU and recur-
rence of pneumonia within 90 days.
The second RCT was a cluster-randomized, crossover study in the
Netherlands in 2015 of 2,283 patients divided among three arms:
β -lactam alone, β -lactam with a macrolide, and fluoroquinolone
alone.33 The mortality in each group was 9.0%, 11.1% and 8.8%,
respectively. Analyses were compared relative to the β -lactam
alone group, which showed noninferior results with confidence
intervals crossing 1. The major limitation of the study was the
fact that 39% of the patients in the β -lactam monotherapy group
received an antimicrobial covering an atypical pathogen at some
point during the hospitalization.
A prospective, observational English study evaluated 5,240 pa-
tients who received either a β -lactam alone or a β -lactam plus
a macrolide.22 Mortality was 26.8% in the monotherapy group
and 23.0% in the combination therapy group; P=0.001. ICU ad-
mission, need for mechanical ventilation, and need for inotropic
support were not statistically different.
One early retrospective study evaluated length of stay and mortal-
ity based on the use of a macrolide in particular. With <100 pa-
tients enrolled, however, statistical significance was not expected,
nor attained.23 Another larger study in 1999 of Medicare patients
aged ≥65 years recorded 30-day mortality for patients receiving
various antimicrobial regimens.24 Those treated with a fluoro-
quinolone or cephalosporin plus a macrolide had lower 30-day
mortality compared to those who received a cephalosporin alone.
During this same time period, there were studies that did not
find a difference with the addition of a macrolide to CAP treat-
ment. A small single center study in an urban teaching hospital
in Malaysia evaluated patients with and without macrolide ther-
apy for CAP.25 Among 141 patients, mortality was 9% in each
group. They did perform a subgroup analysis on the severe pa-
tients, but there were too few for any statistical difference. A
multi-institutional study in Spain of 638 patients with CAP due to
S. pneumoniae compared mortality between different antimicro-
bial groups with the reference group having received a β -lactam
plus a macrolide.28 Neither the β -lactam group nor the fluoro-
quinolone group was statistically different. A separate interna-
tional study in four centers with 340 patients with CAP compli-
cated by pneumococcal bacteremia compared outcomes between
patients who received a β -lactam alone (n=261) to those who
received a β -lactam plus a macrolide (n=79).27 Predictors of
death after multivariate analysis were age, pneumonia in ≥2 lung
lobes and higher severity of disease, but not antimicrobial regi-
men. The mortality for the β -lactam group was 11% vs 19% for
the β -lactam plus a macrolide group (P=0.08). A study from
three centers in Germany, Israel, and Italy compared mortality
in CAP patients who received either a β -lactam (n=169) or a β -
lactam plus a macrolide (n=282).26 The mortality was 22% vs
7% (P=0.0001), respectively, but when the authors adjusted for
confounding factors using propensity score matching to account
for differences in each group, they were only able to compare 27
patients in each group, erasing any statistical difference. The dif-
ferences they accounted for, and for which they excluded patients
from analysis, were septic shock, mental status changes, and hav-
ing an infiltrate on chest radiograph.
In the last ten years, studies have been designed to determine
if combination therapy or fluoroquinolone therapy is associated
© ULJRI 2017 Vol 1, (1) 29–34 | 31
with better outcomes. Among 2209 CAP Medicare patients in
the US treated with a macrolide or with a fluoroquinolone, mul-
tivariable analysis showed that regimens containing a macrolide
had lower in-hospital mortality (P=0.01), lower 30-day mortal-
ity (P=0.007), and lower 30-day readmission rates (P=0.004).29
In a study from a VA hospital in New York, 515 patients either
received combination or fluoroquinolone therapy for CAP.34 Im-
proved mortality was found in patients with severe (PSI risk class
V) CAP. For these severe patients, 14-day mortality for the β -
lactam plus a macrolide group was 8.2% versus 28% for the flu-
oroquinolone group (P=0.02); and 30-day mortality was 18.4%
vs 36.6% (P=0.05), respectively.
A subsequent study in Texas evaluated mortality in patients with
severe CAP.35 Patients were identified by ICD-9 coding, had pos-
itive imaging for pneumonia, and fulfilled the traditional crite-
ria for severe sepsis with at least one organ dysfunction as de-
fined by Bone et al.36 IDSA/ATS guideline-concordant therapy
was determined in a macrolide group (97%) and a non-macrolide
group (63%). Longer-term outcomes were assessed as 30- and
90-day mortality in each group. Among 237 patients, 44% re-
ceived a macrolide. The 30-day mortality for the β -lactam plus
a macrolide group versus the non-macrolide group was 11% vs
29% (P=0.001), while the 90-day mortality was 12% vs 34%, re-
spectively. Interestingly, among patients with macrolide-resistant
pathogens, the macrolide group had a lower risk of dying within
24 days than the non-macrolide group by multivariable analysis
(HR 0.10, 95% CI 0.02-0.49; P=0.005). A follow-up study in-
cluded ICU patients, all of whom received guideline-concordant
therapy, who were in a β -lactam plus a macrolide group or a β -
lactam plus a fluoroquinolone group.37 The 30-day mortality for
the macrolide containing regimen group was 26% vs. 46% for the
fluoroquinolone containing regimen group (P=0.04). This statis-
tical difference was maintained after adjusting for etiology and
severity (HR 0.48%, 95% CI 0.23-0.97, P=0.04).
Outside of the US, including some countries in Europe, guide-
lines recommend using a β -lactam alone in some in-patients with
CAP. A study from Germany evaluated ~1800 hospitalized pa-
tients with CAP who were either treated with a β -lactam alone or
a β -lactam plus a macrolide, but there were only enough patients
with lower risk (CRB65 score 0, 1 or 2) to statistically analyze.38
Among 827 patients who received a β -lactam plus a macrolide
and 919 who received a β -lactam alone, the 14-day mortality
was only different for those with a CRB-65 score of 2 (2.9% vs
11.4%, respectively). There was no difference for those with a
lower CRB-65 score or for any severity group when evaluating
30-day mortality.
At least two meta-analyses have been performed comparing an-
timicrobial treatment for CAP. The first was in 2012 and reviewed
12 out-patient, and four in-patient studies from 1993 to 2005.39
Most patients had mild to moderate CAP. Each study that was
reviewed compared regimens that included a fluoroquinolone to
regimens that included a macrolide. For 30-day mortality, there
was no difference. Clinical failure was defined as persistence of
signs and symptoms to the extent that treatment was changed, or
there was a lack of radiographic improvement within four weeks.
Clinical failure was more frequent with a macrolide containing
regimen than a fluoroquinolone containing regimen (relative risk
(RR) 0.78, 95% CI, 0.67-0.91). Microbiological failure was pre-
sumed to be growth of the organism from a specimen collected
after treatment completed. This outcome was also lower with
fluoroquinolones (RR 0.63, 95% CI, 0.49-0.81). Although flu-
oroquinolones had less clinical and microbiological failure, the
clinical significance of the advantage was deemed to be unclear.
Fluoroquinolones were also favored regarding the frequency of
adverse events, which led to the practical benefit of more com-
pletions of a full course of the antibiotic.
The other meta-analysis was in 2016, and reviewed 14 studies
from 1999 to 2015 including hospitalized patients exclusively.40
Each study that was reviewed compared either a β -lactam plus a
macrolide or a fluoroquinolone alone to a β -lactam alone. Among
data provided, 17 antimicrobial comparisons were available to
analyze from the 14 studies. All of the studies except one had
an odds ratio that favored initially prescribing a β -lactam plus
a macrolide or a fluoroquinolone over a β -lactam alone. Ten
of the studies had a 95% CI that did not cross 1 supporting
a β -lactam plus a macrolide or a fluoroquinolone alone over a
β -lactam alone. These results support the IDSA/ATS guidelines
for CAP. The two meta-analyses support the general finding that
a statistical difference is stronger as the population studied has
more severe disease.
4 Conclusions
After years of observational studies evaluating the use of a reg-
imen containing a macrolide, two RCTs were performed, but
with antagonistic conclusions–one that found that a β -lactam
alone for patients with CAP was noninferior to a β -lactam plus
a macrolide, and one that did not. Because of the varying data,
some CAP guidelines from outside of the US allow for β -lactam
monotherapy in certain patients. But, in light of the different
populations studied in the RCTs (one exclusively in-patients, one
a mix of in- and out-patients), the limitations of the RCTs, and
the great majority of observational studies that favor the use of a
macrolide containing regimen for CAP, the recommended therapy
by IDSA/ATS at this time is either a β -lactam plus a macrolide or
a fluoroquinolone alone for hospitalized patients with CAP.
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